{
  "source": "PA-Med-Nec-Velsipity.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2335-4\nProgram Prior Authorization/Medical Necessity\nMedication Velsipity™ (etrasimod)*\n*Velsipity is excluded from coverage for the majority of our benefits\nP&T Approval Date 4/2024, 10/2024, 11/2024, 4/2025\nEffective Date 6/1/2025\n1. Background:\nVelsipity (etrasimod) is a sphingosine 1-phosphate receptor modulator indicated for the\ntreatment of moderately to severely active ulcerative colitis in adults.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Velsipity will be approved based on all of the following criteria:\na. Diagnosis of moderately to severely active ulcerative colitis (UC)\n-AND-\nb. One of the following:\n(1) Patient has had prior or concurrent inadequate response to a therapeutic course\nof oral corticosteroids and/or immunosuppressants (e.g., azathioprine, 6-\nmercaptopurine)\n-OR-\n(2) Patient has been previously treated with a targeted immunomodulator FDA-\napproved for the treatment of ulcerative colitis as documented by claims history\nor submission of medical records (Document drug, date, and duration of\ntherapy) [e.g., adalimumab, Simponi (golimumab), ustekinumab, Xeljanz\n(tofacitinib), Rinvoq (upadacitinib)]\n-AND-\nc. History of failure, contraindication, or intolerance to three of the following\npreferred products (document drug, date, and duration of trial):\n(1) One of the preferred adalimumab productsb\n(2) Entyvio (vedolizumab)\n(3) Omvoh (mirikizumab-mrkz)\n(4) Rinvoq (upadacitinib)\n(5) Simponi (golimumab)\n© 2025 UnitedHealthcare Services, Inc.\n1\n(6) Skyrizi (risankizumab)\n(7) One of the preferred ustekinumab productsb\n(8) Tremfya (guselkumab)\n(9) Xeljanz/Xeljanz XR (tofacitinib)\n-AND-\nd. History of failure, contraindication, or intolerance to Zeposia (ozanimod) (document\ndate and duration of trial):\n-AND-\ne. Patient is not receiving Velsipity in combination with a targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abata",
    "nd duration of trial):\n-AND-\ne. Patient is not receiving Velsipity in combination with a targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib), ustekinumab, Skyrizi (risankizumab),\nOmvoh (mirikizumab-mrkz), Entyvio (vedolizumab)]\n-AND-\nf. Prescribed by or in consultation with a gastroenterologist\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Velsipity will be approved based on both of the following criteria:\na. Documentation of positive clinical response to Velsipity therapy\n-AND-\nb. Patient is not receiving Velsipity in combination with a targeted immunomodulator\n[e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia\n(abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib), ustekinumab, Skyrizi (risankizumab), Omvoh (mirikizumab-mrkz),\nEntyvio (vedolizumab)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\nb For a list of preferred products please reference drug coverage tools.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\n© 2025 UnitedHealthcare Services, Inc.\n2\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Exclusion: Velsipity is excluded from coverage for the majority of our benefits\n• Supply limits may be in place.\n4. References:\n1. Velsipity [package insert]. New York, NY: Pfizer Inc.; November 2023.\n2. Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA clinical practice guidelines on the\nmanagement of moderate to se",
    "ferences:\n1. Velsipity [package insert]. New York, NY: Pfizer Inc.; November 2023.\n2. Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA clinical practice guidelines on the\nmanagement of moderate to severe ulcerative colitis. Gastroenterology. 2020; 158(5):1450-61.\nProgram Prior Authorization/Medical Necessity – Velsipity (etrasimod)\nChange Control\n4/2024 New program.\n10/2024 Updated step requirement noting Adalimumab-adaz (unbranded\nHyrimoz), Amjevita for Nuvaila, and Humira as preferred adalimumab\nproducts with no change to clinical intent. Removed preferred\nadalimumab footnote. Added Entyvio, Omvoh and Skyrizi as step\ntherapy agents.\n11/2024 Added Tremfya as a step therapy agent.\n4/2025 Removed examples for adalimumab in step therapy. Changed Stelara\nstep therapy to “One of the preferred ustekinumab productsc”. Changed\nStelara example to Ustekinumab. Added the footnote “For a list of\npreferred products please reference drug coverage tools.”\n© 2025 UnitedHealthcare Services, Inc.\n3"
  ]
}